DARIOHEALTH CORP. (NASDAQ:DRIO) Files An 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

On March 15, 2018, the Audit Committee of the Board of Directors (the “Audit Committee”) of DarioHealth Corp. (the “Company”), after discussion with Company management and Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global (“KFGK”), the Company’s independent registered public accounting firm, determined that the Quarterly Reports on Form 10-Q for the quarters ended March 30, 2017, June 30, 2017 and September 30, 2017 (collectively, the “Prior Periods”) previously filed with the Securities and Exchange Commission should no longer be relied upon.

This determination occurred after the Company’s management identified a certain error recorded for the relevant periods relating to the re-measurement of certain liability warrants before their reclassification from liability to equity in the period ended March 31, 2017. As a result of this error, the Company will reflect an increased net loss from the Prior Periods but the restatements will not have an impact on the Company’s stockholder’s equity for the Prior Periods. The Company intends to file amendments to the Quarterly Reports on Form 10-Q for the Prior Periods as soon as possible in order to correct such errors in the financial statements, as well as make the necessary conforming changes in the relevant “Management’s Discussion and Analysis of Financial Condition and Results of Operations” discussions resulting from the adjustments provided above. In light of the error identified above, the Company’s previously filed financial statements and other financial information contained in the Quarterly Reports on Form 10-Q for the Prior Periods should no longer be relied upon.

The chair of the Company’s audit committee, on behalf of the audit committee, and the Company’s management have discussed the matters disclosed in this Item 4.02(a) of this Current Report on Form 8-K with KFGK.

About DARIOHEALTH CORP. (NASDAQ:DRIO)

DarioHealth Corp, formerly Labstyle Innovations Corp, is a digital health (mHealth) company. The Company is engaged in developing and commercializing a technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. The Company’s product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with a pocket-sized, blood glucose monitoring device, Dario Smart Meter. The Dario product is a digital diabetes management solution utilizing its technology delivered through a software application available for iPhone or Android and cloud-based data services with a blood glucose monitoring system device. Dario allows users to record, analyze, transmit and store various data points, such as glucose level, insulin and carbohydrate intake. It markets the Dario Smart Diabetes Management Solution in the Netherlands and New Zealand.